1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+ IPI) or NIVO alone
Background 5-year outcomes of patients (pts) with a CR to NIVO+ IPI or NIVO alone and
factors associated with continued CR or relapse are unknown. The current pooled analysis
addresses these key questions, including a 12-mo CR landmark analysis used to decrease
the time guarantee bias. Methods In this post hoc analysis, 5-yr data were pooled from the
phase III CheckMate 066 and 067 studies and the phase II CheckMate 069 study of pts with
treatment-naive, advanced melanoma. Analyzed pts received either the approved regimen …
factors associated with continued CR or relapse are unknown. The current pooled analysis
addresses these key questions, including a 12-mo CR landmark analysis used to decrease
the time guarantee bias. Methods In this post hoc analysis, 5-yr data were pooled from the
phase III CheckMate 066 and 067 studies and the phase II CheckMate 069 study of pts with
treatment-naive, advanced melanoma. Analyzed pts received either the approved regimen …
